Dermatitis: Clinical Trials

20 trials for Dermatitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

20 unknown. 20 Phase 1, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 120Unknown 20
Phase 28Unknown 8

Follow Dermatitis: new trials by email Literature Review of Dermatitis trials Research Report on Dermatitis

Trials (filtered) newest first · largest first

All 20 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis.
GR2002 injection - Atopic Dermatitis
Phase 1UnknownGenrix (Shanghai) Biopharmaceutical Co., Ltd.402023-12-012023-12-18
A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults
FB825 or Placebo in subcutaneous route, FB825 in intravenous route - Atopic Dermatitis
Phase 1UnknownOneness Biotech Co., Ltd.222023-05-032024-01-26
A First-in-Human Study of QY211 Gel in Adult Subjects
0.1% QY211 Gel or placebo, 0.3% QY211 Gel or placebo, 0.8% QY211 Gel or placebo - Atopic Dermatitis
Phase 1UnknownE-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.562023-03-012023-05-06
Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis.
Single Dose, Double Dose - Chronic Conjunctivitis, Stevens-Johnson Syndrome
Phase 1 / Phase 2UnknownInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz202022-11-112024-07-08
A Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis
2mg QY201 tablets or 2mg QY201 placebo,BID, 5mg QY201 tablets or 5mg QY201 placebo,BID, 10mg QY201 tablets or 10mg QY201 placebo,QD - Atopic Dermatitis
Phase 1 / Phase 2UnknownE-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.2602022-10-012022-09-02
A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects
TQH2722 injection, Placebo to match TQH2722 - Atopic Dermatitis
Phase 1UnknownChia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.482022-06-012022-06-08
BH4 in the Prevention and Treatment of Radiation-induced Skin Reactions for Head and Neck Squamous Cell Carcinoma (Including Nasopharyngeal Carcinoma)
Sapropterin dihydrochloride tablets - Head and Neck Squamous Cell Carcinoma
Phase 1UnknownWest China Hospital182022-05-012022-03-28
SAD/MAD Safety and PK Study of RBN-3143 in Healthy and Atopic Dermatitis Subjects
RBN-3143 - Atopic Dermatitis
Phase 1UnknownRibon Therapeutics, Inc.722022-03-072023-10-23
A Study for Assessing the Efficacy and Safety of Tetrahydrobiopterin in Radiation-Induced Skin Injury
Tetrahydrobiopterin - Radiation-Induced Dermatitis
Phase 1UnknownWest China Second University Hospital452022-03-012022-02-28
A Safety, Tolerability, and Dermal Reactogenicity Study of PDC-APB
PDC-APB, Placebo - Contact Dermatitis
Phase 1UnknownHapten Sciences, Inc.322021-11-012021-08-27
MH004 Topical Cream in Healthy Adult Volunteers and Participants With Atopic Dermatitis or Rheumatoid Arthritis
MH004 Ia(0.1%), MH004 Ia(0.3%), MH004 Ia(1%) - Atopic Dermatitis, Rheumatoid Arthritis
Phase 1UnknownMinghui Pharmaceutical Pty Ltd722021-04-012021-03-24
Safety and Explore the Efficacy of Multiple Doses of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis
FURESTEM-AD inj - Atopic Dermatitis
Phase 1 / Phase 2UnknownKang Stem Biotech Co., Ltd.962021-01-272022-01-11
Efficacy of the Mepitel® Film on the Prevention of Radiodermatitis in the Inguinal Fold.
Mepitel® film, Flamigel® - Radiodermatitis, Radiation Toxicity
Phase 1 / Phase 2UnknownJules Bordet Institute352021-01-012020-11-05
Topical Cream SNG100 for Treatment in Moderate Atopic Dermatitis Subjects.
Hydrocortisone Acetate 1% Cream, Mometasone Furoate, SNG100 - Atopic Dermatitis
Phase 1UnknownSeanergy Dermatology Ltd.662021-01-012020-11-04
Open-Label Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis
RVT-501 0.5% topical ointment - Atopic Dermatitis
Phase 1UnknownDermavant Sciences GmbH242018-02-052018-05-11
Ganoderma Tea on Eczema Patient
A Master Ganoderma Detox Tea - Eczema
Phase 1 / Phase 2UnknownHong Kong Baptist University302015-08-012015-08-27
MARY DUOL REPAIR BALM IN THE PREVENTION OR REDUCING ANTINEOPLASIC AGENTS' SKIN TOXICITY
BALM ARM, PLACEBO ARM - Dermatitis, Adverse Drug Reaction
Phase 1 / Phase 2UnknownBasque Health Service862014-02-012016-08-02
Evaluation of A-1 Cool Cream Efficacy for Treatment Atopic Dermatitis
A -1 Cool Cream,Vaselin ointment - ATOPIC DERMATITIS
Phase 1 / Phase 2UnknownHadassah Medical Organization302011-07-012011-07-06
Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients
Botulinum toxin - Parkinson Disease, Parkinsonism
Phase 1UnknownRabin Medical Center402009-05-012008-10-07
Olive Oil With Omega 3 to Treat Stasis Dermatitis
olive oil and omega 3 in a combined cream - Dermatitis
Phase 1 / Phase 2UnknownAssaf-Harofeh Medical Center302007-01-012007-01-11

Narrower conditions

Dermatitis, Atopic (11)  ·  Radiodermatitis (3)  ·  Arthritis, Rheumatoid (1)  ·  Dermatitis, Contact (1)  ·  Dermatitis, Seborrheic (1)  ·  Drug Eruptions (1)  ·  Eczema (1)  ·  Nasopharyngeal Carcinoma (1)  ·  Parkinson Disease (1)  ·  Parkinsonian Disorders (1)  ·  Pemphigoid, Bullous (1)  ·  Radiation Injuries (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Stevens-Johnson Syndrome (1)

Broader conditions

Skin Diseases (20)  ·  Skin and Connective Tissue Diseases (20)  ·  Skin Diseases, Eczematous (14)  ·  Hypersensitivity (12)  ·  Immune System Diseases (12)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (11)  ·  Genetic Diseases, Inborn (11)  ·  Hypersensitivity, Immediate (11)  ·  Skin Diseases, Genetic (11)  ·  Wounds and Injuries (3)  ·  Autoimmune Diseases (2)  ·  Chemically-Induced Disorders (2)  ·  Drug Hypersensitivity (2)  ·  Drug-Related Side Effects and Adverse Reactions (2)

Interventions

sapropterin (2)  ·  Botulinum Toxins (1)  ·  Docosahexaenoic Acids (1)  ·  Exercise (1)  ·  Injections, Subcutaneous (1)  ·  Mometasone Furoate (1)  ·  Ointments (1)  ·  Olive Oil (1)  ·  hydrocortisone acetate (1)  ·  methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)amino)carbonyl)benzoate (1)

Sponsors

E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. (2)  ·  Assaf-Harofeh Medical Center (1)  ·  Basque Health Service (1)  ·  Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (1)  ·  Dermavant Sciences GmbH (1)  ·  Genrix (Shanghai) Biopharmaceutical Co., Ltd. (1)  ·  Hadassah Medical Organization (1)  ·  Hapten Sciences, Inc. (1)  ·  Hong Kong Baptist University (1)  ·  Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz (1)  ·  Jules Bordet Institute (1)  ·  Kang Stem Biotech Co., Ltd. (1)  ·  Minghui Pharmaceutical Pty Ltd (1)  ·  Oneness Biotech Co., Ltd. (1)  ·  Rabin Medical Center (1)

Countries

China (4)  ·  Spain (2)  ·  United States (2)  ·  Australia (1)  ·  Hong Kong (1)  ·  Israel (1)  ·  New Zealand (1)  ·  South Korea (1)

Top investigators

Arie Bass, MD (1)  ·  Cheng Zhou, PHD (1)  ·  James Lee, MD, PhD (1)  ·  James Marks, MD (1)  ·  Jianzhong Zhang, PHD (1)  ·  LiMing Wu, Ph.D, M.D (1)  ·  Patricia Seaone, MD (1)  ·  Raquel Cobos, Msc (1)  ·  Shi Ping Zhang, PhD (1)  ·  Thomas Polasek, MD (1)  ·  Xingchen Peng, Ph.D (1)  ·  Yuval Ramot, Prof. (1)

Results publications

PMID 28596000, PMID 40221092